Pfizer to give a keynote address on reviving covalent drug design in oncology at SMi’s 15th annual event this February
Posted: 29 January 2016 | SMi Group | No comments yet
SMi group reports: Doug Johnson, Research Fellow at Pfizer will be giving a keynote address on Day 1 at the SMi’s 15th annual Advances and Progress in Drug Design conference…
SMi group reports: Doug Johnson, Research Fellow at Pfizer will be giving a keynote address on Day 1 at the SMi’s 15th annual Advances and Progress in Drug Design conference (15-16 February 2016, Holiday Inn Kensington Forum, London) on: Reviving covalent drug design: Discovery of PF-04457845, an irreversible FAAH inhibitor with exquisite selectivity.
His presentations topics will include:
- The unique benefits of small molecule covalent drug candidates
- Activity-based protein profiling and clickable probes to evaluate selectivity of covalent binding
- Biomarkers and PET ligand to determine target engagement in humans
With the recent industry updates, this year’s Advances and Progress in Drug Design event will focus on enabling biophysical tools and highlight key advancements in protein-based drug discovery. It will take a closer look at combined HTS and FBDD methods for lead generation and the application of biophysical methods such as: X-Ray Crystallography, NMR, biocore and ITC to aid the prioritization of target inhibitors.
Automation now plays a central role in discovery. From self-driving laboratories to real-time bioprocessing
This report explores how data-driven systems improve reproducibility, speed decisions and make scale achievable across research and development.
Inside the report:
- Advance discovery through miniaturised, high-throughput and animal-free systems
- Integrate AI, robotics and analytics to speed decision-making
- Streamline cell therapy and bioprocess QC for scale and compliance
- And more!
This report unlocks perspectives that show how automation is changing the scale and quality of discovery. The result is faster insight, stronger data and better science – access your free copy today
Plus, two interactive half-day post-conference workshops:
- A fresh view on molecular recognition: the dynamic perspective – presented by Barcelona University
- Analysis and Application of Ligand Conformation in Drug Design – presented by C4X Discovery
Key speakers in 2016 include:
- Gregg Seigal, Chief Executive Officer, ZoBio
- Doug Johnson, Research Fellow, Pfizer
- Tove Sjögren, Associate Director, AstraZeneca
- Jordi Munoz-Muriedas, Investigator, GSK
- Herman van Vlijmen, Senior Director, Janssen
- Armin Ruf, Section Head, Biostructure, Roche
- Manuel Francisco Molina-Martin, Research Scientist, Eli Lilly, and many more
For the full event agenda/ to register please visit: www.drug-design.co.uk
Alternatively, get in touch with Matthew Apps: +44 20 7827 6093 or e-mail: [email protected]
Those who are interested in attending are advised to register now to avoid disappointment.
Related topics
Biomarkers, High-Throughput Screening (HTS), Screening
Related organisations
Pfizer
